Oramed Pharmaceuticals Inc.

Director's Dealing • Apr 11, 2018

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB Number: 3235-0287 hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person Hexter Joshua						2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director			10% Owner
(Last)	(First) (Middle) 9 ALFASI ST.					3. Date of Earliest Transaction (Month/Day/Year) 04/08/2018								X	Officer (give title below) Chief Operating Officer			Other (specify below)
(Street) (City)	JERUSALEM L3 92302 (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line) X	6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
2. Transaction 1. Title of Security (Instr. 3) Date (Month/Day/Year)					2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. and 5) 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Owned			6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
									Code	V	Amount	(A) or (D)		Price	Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of	8. Price Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code		V (A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	\$7.05	04/08/2018			A		30,000		(1)		04/08/2028	Common Stock	30,000		\$0	30,000		D

Explanation of Responses:

1. The Stock Option will vest in 4 equal installments of 7,500 on each of April 1, 2019, April 1, 2020, April 1, 2021 and April 1, 2022.

/s/ Joshua Hexter 04/10/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL Estimated average burden